Time to revisit the true role of metformin in type 2 diabetes mellitus

References

• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 [2020 Jan 7];41(2):255–323. doi:10.1093/eurheartj/ehz486.
   PubMed Web of Science ®Google Scholar
• Force Members A, Rydén L, Grant PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013 Oct;34(39):3035–3087.
   PubMed Web of Science ®Google Scholar
• Anderson JE. Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes. Diabetes Spectr. 2020;33(2):165–174. doi:10.2337/ds19-0031
   PubMedGoogle Scholar
• Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. published correction appears in BMJ. 2022 Jan 18;376:o109.
   Google Scholar
• Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021 May 11;373(n1091). doi:10.1136/bmj.n1091
   Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9thedition. Diabet Res Clin Pract. 2019 Nov;157:107843.
   PubMed Web of Science ®Google Scholar
• Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes, and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444–470. doi:10.4239/wjd.v5.i4.444
   PubMedGoogle Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229–234.
   PubMed Web of Science ®Google Scholar
• Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33(2):442–449. doi:10.2337/dc09-0749
   PubMed Web of Science ®Google Scholar
• Freeman AM, Pennings N Insulin Resistance. 2022 Jan. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [Updated 2022 Jul 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507839/
   Google Scholar
• Semple RK, Savage DB, Cochran EK, et al. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011 Aug;32(4):498–514.
   PubMed Web of Science ®Google Scholar
• Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. doi:10.3390/ijms21176275
   PubMed Web of Science ®Google Scholar
• Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga diabetes study. J Clin Endocrinol Metab. 2006;91(3):813–819. DOI:10.1210/jc.2005-1005
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Gheewala NM, O’Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol. 2008;51(3):249–255. doi:10.1016/j.jacc.2007.10.016
   PubMed Web of Science ®Google Scholar
• Bell DS, O’Keefe JH, Jellinger P. Postprandial dysmetabo- lism: the missing link between diabetes and cardiovascular events? Endocr Pract. 2008;14:112–124. doi:10.4158/EP.14.1.112
   PubMedGoogle Scholar
• O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyper- lipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100:899–904. doi:10.1016/j.amjcard.2007.03.107
   PubMed Web of Science ®Google Scholar
• Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The third national health and nutrition examination survey, 1988-1994. Diabetes Care. 1998 Apr;21(4):518–524.
   PubMed Web of Science ®Google Scholar
• Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356:213–215. doi:10.1056/NEJMp068177
   PubMed Web of Science ®Google Scholar
• Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and Type 2 diabetes: two diseases with a need for combined treatment strategies - EASO can lead the way. Obes Facts. 2017;10(5):483–492. doi:10.1159/000480525
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–880.doi:10.1038/nature05487
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–887.doi:10.1038/nature05488
   PubMed Web of Science ®Google Scholar
• Albu JB, Lu J, Mooradian AD, et al. Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Obesity (Silver Spring). 2010;18:1046–1054. doi:10.1038/oby.2009.339
   PubMed Web of Science ®Google Scholar
• Zoppini G, Verlato G, Leuzinger C, et al. Body mass index and the risk of mortality in type II diabetic patients from Verona. Int J Obes Relat Metab Disord. 2003;27(2):281–285. doi:10.1038/sj.ijo.802199
   PubMed Web of Science ®Google Scholar
• Czernichow S, Kengne AP, Huxley RR, et al. Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. Eur J Cardiovasc Prev Rehabil. 2011;18(2):312–319. doi:10.1097/HJR.0b013e32833c1aa3
   PubMedGoogle Scholar
• Palmer SC, Strippoli GFM. Metformin as first-line treatment for type 2 diabetes. Lancet. 2018 Jul 14;392(10142):120.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS). Group: effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854–865. doi:10.1016/S0140-6736(98)07037-8
   PubMed Web of Science ®Google Scholar
• Holstein A, Egberts EH. Risk of hypoglycemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405–414. doi:10.1055/s-2003-44287
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386–399. doi:10.7326/0003-4819-147-6-200709180-00178
   PubMed Web of Science ®Google Scholar
• Loi H, Boal F, Tronchere H, et al. Metformin protects the heart against hypertrophic and apoptotic remodeling after myocardial infarction. Front Pharmacol. 2019;10:154. doi:10.3389/fphar.2019.00154
   PubMed Web of Science ®Google Scholar
• Younis A, Eskenazi D, Goldkorn R, et al. The addition of vildagliptin to metformin prevents the elevation of interleukin 1β in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovasc Diabetol. 2017;16(1):69. doi:10.1186/s12933-017-0551-5
   PubMedGoogle Scholar
• Charytan DM, Solomon SD, Ivanovich P, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diab Obes Metab. 2019;21(5):1199–1208. doi:10.1111/dom.13642
   PubMed Web of Science ®Google Scholar
• Rena G, Lang CC. Repurposing metformin for cardiovascular disease. Circulation. 2018;137(5):422–424. doi:10.1161/CIRCULATIONAHA.117.031735
   PubMed Web of Science ®Google Scholar
• van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol. 2018;17(1):94. doi:10.1186/s12933-018-0738-4
   PubMedGoogle Scholar
• Færch K, Amadid H, Nielsen LB, et al. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). BMJ Open. 2017;7(5):5. doi:10.1136/bmjopen-2016-013802
   Google Scholar
• Wurm R, Resl M, Neuhold S, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart. 2016;102(19):1544–1551. doi:10.1136/heartjnl-2015-308711
   PubMed Web of Science ®Google Scholar
• Jong CB, Chen KY, Hsieh MY, et al. Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: a nationwide registry with propensity score- matched analysis. Int J Cardiol. 2019;291:152–157. doi:10.1016/j.ijcard.2019.03.021
   PubMed Web of Science ®Google Scholar
• Campbell JM, Bellman SM, Stephenson MD, et al. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev. 2017;40:31–44. doi:10.1016/j.arr.2017.08.003
   PubMed Web of Science ®Google Scholar
• Varjabedian L, Bourji M, Pourafkari L, et al. Cardioprotection by metformin: beneficial effects beyond glucose reduction. Am J Cardiovasc Drugs. 2018;18(3):181–193. doi:10.1007/s40256-018-0266-3
   PubMed Web of Science ®Google Scholar
• Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96. doi:10.1186/s12933-019-0900-7
   PubMedGoogle Scholar
• Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013 May;36(5):1304–1311.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diab Obes Metab. 2012 Sep;14(9):803–809.
   PubMed Web of Science ®Google Scholar
• Molavi B, Rassouli N, Bagwe S, et al. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 2007;3(6):967–973.
   PubMedGoogle Scholar
• https://www.drugwatch.com/actos/ (Nov 6, 2022).
   Google Scholar
• Nyambuya TM, Dludla PV, Mxinwa V, et al. The impact of metformin and aspirin on T-cell mediated inflammation: a systematic review of in vitro and in vivo findings. Life Sci. 2020 Aug 15;255:117854.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group; Buse JB, Bigger JT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007 Jun 18;99(12A):21i-33i.
   Google Scholar
• ADVANCE Collaborative Group; Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129–139.
   PubMed Web of Science ®Google Scholar
• Monte SV, Schentag JJ, Adelman MH, et al. Glucose supply and insulin demand dynamics of antidiabetic agents. J Diabetes Sci Technol. 2010 Mar 1;4(2):365–381.
   PubMedGoogle Scholar
• Kanie T, Mizuno A, Yoneoka D, et al. Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis. Cochrane Database Syst Rev. 2020 Jun 24;2020(6): CD013650. doi:10.1002/14651858.CD013650
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019 Oct 1;322(13):1271–1282.
   PubMed Web of Science ®Google Scholar
• Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740–751.
   PubMed Web of Science ®Google Scholar
• Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009 Mar 23;169(6):616–625.
   PubMedGoogle Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet. 1998 Sep 12;352(9131):854–865. doi:10.1016/S0140-6736(98)07037-8
   PubMed Web of Science ®Google Scholar
• Roumie CL, Chipman J, Min JY, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA. 2019 Sep 24;322(12):1167–1177.
   PubMed Web of Science ®Google Scholar
• Top WMC, Kooy A, Stehouwer CDA. Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia. Pharmaceuticals (Basel). 2022 Mar 4;15(3):312.
   PubMedGoogle Scholar
• Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism. 2022 May;130:155160. doi:10.1016/j.metabol.2022.155160
   PubMed Web of Science ®Google Scholar
• Dihoum A, Rena G, Pearson ER, et al. Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease. Expert Opin Investig Drugs. 2023 Apr;32(4):291–299.
   PubMed Web of Science ®Google Scholar